Medtronic to Acquire SPR Therapeutics for $650 Million to Expand Pain Portfolio

In a move reflecting the ongoing consolidation in the medical technology sector, Medtronic has announced its intention to acquire SPR Therapeutics in a deal valued at approximately $650 million. The acquisition will integrate the FDA-cleared SPRINT PNS System into Medtronic's chronic pain treatment portfolio, strengthening its neuromodulation business. According to reports, the transaction is expected to close by fiscal year 2027, marking a strategic expansion into peripheral nerve stimulation technologies.

This acquisition occurs amid intensifying competition in the medical device industry, as major players seek to bolster margins through specialized high-growth segments. In comparison, peer firm Boston Scientific (BSX) recently reported strong growth in its neuromodulation division, while Abbott (ABT) continues to expand its wireless stimulation offerings. Per market data, the addition of SPR’s non-opioid pain management technology positions Medtronic to capture a larger share of the chronic pain market, which is increasingly pivoting away from traditional pharmaceutical interventions.

Regarding market performance, MDT stock stood at $88.45 (close May 21, 2026) as investors weigh the long-term integration benefits against the 2027 closing timeline. Traders should watch for upcoming earnings calls and regulatory filings for further clarity on the deal's impact on capital allocation. Additionally, upcoming global economic catalysts, such as inflation data from Canada and the US scheduled for next week, may influence broader healthcare sector sentiment.